N-(4-Aminobenzoyl)-L-glutamic acid; 4271-30-1; (S)-2-(4-Aminobenzamido)pentanedioic acid; N-(p-Aminobenzoyl)glutamic acid; 4-Aminobenzoylglutamic acid; p-Aminobenzoylglutamic acid; p-Aminobenzoyl-L-glutamic acid; H-4-Abz-Glu-OH; (2S)-2-[(4-aminobenzoyl)amino]pentanedioic acid; L-N-(p-Aminobenzoyl)glutamic acid; L-Glutamic acid, N-(4-aminobenzoyl)-; CHEBI:61114; (4-Aminobenzoyl)-L-glutamic acid; N-(p-Aminobenzoyl)-L-glutamic acid; 9BKY99A8HJ; 532-63-8; CHEMBL3278332; Folic acid Impurity A; N-(4-aminobenzene-1-carbonyl)-L-glutamic acid; 4-AMINOBENZOIC GLUTAMIC ACID; (2S)-2-[(4-Aminobenzoyl)amino]pentanedioic Acid (N-(4-Aminobenzoyl)-L-glutamic Acid); UNII-9BKY99A8HJ; N-(4-Aminobenzoyl)glutamic acid; MFCD00042821; NSC-71042; N-4-Aminobenzoyl-L-glutamic acid; EINECS 224-261-7; NSC 71042; N-(p-Aminobenzoyl)glutamic acid (VAN); 4-Aminobenzoylglutamate; Methotrexate Impurity K; Glutamic acid, N-(p-aminobenzoyl)-, L-; SCHEMBL63083; 4-aminobenzoyl-l-glutamic acid; p-Amino Benzamide Glutamic Acid; DTXSID10873641; BCP15199; ZINC1696610; BDBM50542900; AKOS010366208; AKOS015855631; CS-W012429; HY-W011713; (P-AMINOBENZOYL)-L-GLUTAMIC ACID; AMINOBENZOYL-L-GLUTAMIC ACID, P-; 4-AMINOBENZOYLGLUTAMIC ACID [DSC]; DS-15609; (-)-N-(P-AMINOBENZOYL)GLUTAMIC ACID; 4-AMINOBENZOYLGLUTAMIC ACID [USP-RS]; A0442; AM20060626; METHOTREXATE IMPURITY K [EP IMPURITY]; A-5000; A825991; CALCIUM FOLINATE IMPURITY A [EP IMPURITY]; N-(4-AMINOBENZOYL)-L-GLUTAMIC ACID [MI]; (2S)-2-[(4-aminophenyl)formamido]pentanedioic acid; N-(4-Aminobenzoyl)-L-glutamic acid, >=98% (TLC); Q27130821; (2S)-2((4-AMINOBENZOYL)AMINO)PENTANEDIOIC ACID; Folic acid impurity A, European Pharmacopoeia (EP) Reference Standard; 4-Aminobenzoylglutamic acid, United States Pharmacopeia (USP) Reference Standard; N-(4-aminobenzoyl)-L-Glutamic acid (Folic Acid Imp A), Pharmaceutical Secondary Standard; Certified Reference Material